Antisense oligonucleotides for the treatment of dyslipidemia

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 950-960

  Gouni Berthold, I ^a   Berthold, H K ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antisense oligonucleotides; ApoB; Hyperlipidemia; LDL cholesterol; Mipomersen; PCSK9

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; COLESEVELAM; DIACYLGLYCEROL ACYLTRANSFERASE 1; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PEPTIDE NUCLEIC ACID; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; PLACEBO; PROPROTEIN CONVERTASE KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BASE PAIRING; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY LIVER; FEVER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE ERYTHEMA; LUMBAR STENOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT;

ANIMALS; APOLIPOPROTEIN B-100; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; SERINE ENDOPEPTIDASES;

EID: 79958242403     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428830     Document Type: Article

References (129)

1. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with orwithout ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
2. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety ofmore intensive lowering of LDL cholesterol: a meta-analysis ofdata from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recentclinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines. Circulation 2004; 110: 227-39.
4. Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities in the treatment and control of cardiovascularrisk factors in type 2 diabetes. Diabetes Care 2008; 31: 1389-91.
5. Li M, Ong KL, Tse HF, Cheung BM. Utilization of lipid loweringmedications among adults in the United States 1999-2006. Atherosclerosis 2010; 208: 456-60.
6. Kashani A, Phillips CO, Foody JM, et al. Risks associated withstatin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-97.
7. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild tomoderate muscular symptoms with high-dosage statin therapy inhyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-14.
8. Abifadel M, Pakradouni J, Collin M, et al. Strategies for proproteinconvertase subtilisin kexin 9 modulation: a perspective on recentpatents. Expert Opin Ther Pat 2010; 20: 1547-71.
9. Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesisinhibition: results from clinical trials. Curr Opin Lipidol 2010; 21:319-23.
10. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55: 61-95.
11. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low densitylipoproteins contain a single molecule of apolipoprotein B. J LipidRes 1988; 29: 1461-73.
12. Thomas T, Ginsberg H. Development of apolipoprotein B antisensemolecules as a therapy for hyperlipidemia. Curr Atheroscler Rep 2010; 12: 58-65.
13. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990; 82: 1574-94.
14. Segrest JP, Jones MK, De LH, Dashti N. Structure ofapolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001;42: 1346-67.
15. Kesaniemi YA, Witztum JL, Steinbrecher UP. Receptor-mediatedcatabolism of low density lipoprotein in man. Quantitation usingglucosylated low density lipoprotein. J Clin Invest 1983; 71: 950-9.
16. Steinberg D. Lipoproteins and atherosclerosis. A look back and alook ahead. Arteriosclerosis 1983; 3: 283-301.
17. Genest J. Lipoprotein disorders and cardiovascular risk. J InheritMetab Dis 2003; 26: 267-87.
18. Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR. Lipiddisorders and mutations in the APOB gene. Clin Chem 2004; 50:1725-32.
19. Shen H, Damcott CM, Rampersaud E, et al. Familial defectiveapolipoprotein B-100 and increased low-density lipoproteincholesterol and coronary artery calcification in the old order amish. Arch Intern Med 2010; 170: 1850-5.
20. Segrest JP, Jones MK, De LH, Dashti N. Structure ofapolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001;42: 1346-67.
21. Davidson NO, Shelness GS. APOLIPOPROTEIN B: mRNAediting, lipoprotein assembly, and presecretory degradation. AnnuRev Nutr 2000; 20: 169-93.
22. Jackson KG, Williams CM. Apolipoprotein B-48: comparison offasting concentrations measured in normolipidaemic individualsusing SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 2004; 176: 207-17.
23. Farese RV, Jr., Ruland SL, Flynn LM, Stokowski RP, Young SG. Knockout of the mouse apolipoprotein B gene results in embryoniclethality in homozygotes and protection against diet-inducedhypercholesterolemia in heterozygotes. Proc Natl Acad Sci U S A 1995; 92: 1774-8.
24. Lin X, Schonfeld G, Yue P, Chen Z. Hepatic fatty acid synthesis issuppressed in mice with fatty livers due to targeted apolipoproteinB38.9 mutation. Arterioscler Thromb Vasc Biol 2002; 22: 476-82.
25. Srivastava RA, Toth L, Srivastava N, et al. Regulation of theapolipoprotein B in heterozygous hypobetalipoproteinemic knockoutmice expressing truncated apoB, B81. Low production andenhanced clearance of apoB cause low levels of apoB. Mol CellBiochem 1999; 202: 37-46.
26. Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia:genetics and metabolism. Cell Mol Life Sci 2005; 62: 1372-8.
27. Schonfeld G, Patterson BW, Yablonskiy DA, et al. Fatty liver infamilial hypobetalipoproteinemia: triglyceride assembly intoVLDL particles is affected by the extent of hepatic steatosis. JLipid Res 2003; 44: 470-8.
28. Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familialhypobetalipoproteinemia: roles of the APOB defects, intraabdominaladipose tissue, and insulin sensitivity. J Lipid Res 2004;45: 941-7.
29. Sankatsing RR, Fouchier SW, de HS, et al. Hepatic andcardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2005; 25: 1979-84.
30. Thomas T, Ginsberg H. Development of apolipoprotein B antisensemolecules as a therapy for hyperlipidemia. Curr Atheroscler Rep 2010; 12: 58-65.
31. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familialhypercholesterolemia and coronary heart disease: a HuGEassociation review. Am J Epidemiol 2004; 160: 421-9.
32. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P,Nordestgaard BG. Association of mutations in the apolipoprotein Bgene with hypercholesterolemia and the risk of ischemic heartdisease. N Engl J Med 1998; 338: 1577-84.
33. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55: 61-95.
34. Ito MK. ISIS 301012 gene therapy for hypercholesterolemia: sense,antisense, or nonsense? Ann Pharmacother 2007; 41: 1669-78.
35. Aboul-Fadl T. Antisense oligonucleotides: the state of the art. CurrMed Chem 2005; 12: 2193-214.
36. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: fromdesign to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-40.
37. Kurreck J. Antisense technologies. Improvement through novelchemical modifications. Eur J Biochem 2003; 270: 1628-44.
38. Crooke ST. Progress in antisense technology: the end of thebeginning. Methods Enzymol 2000; 313: 3-45.
39. McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM. Characterization of a potent and specific class ofantisense oligonucleotide inhibitor of human protein kinase Calphaexpression. J Biol Chem 1999; 274: 1715-22.
40. Amantana A, Iversen PL. Pharmacokinetics and biodistribution ofphosphorodiamidate morpholino antisense oligomers. Curr OpinPharmacol 2005; 5: 550-5.
41. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. Cross-species pharmacokinetic comparison from mouse to man of asecond-generation antisense oligonucleotide, ISIS 301012,targeting human apolipoprotein B-100. Drug Metab Dispos 2007;35: 460-8.
42. Henry SP, Geary RS, Yu R, Levin AA. Drug properties of secondgenerationantisense oligonucleotides: how do they measure up totheir predecessors? Curr Opin Investig Drugs 2001; 2: 1444-9.
43. Jason TL, Koropatnick J, Berg RW. Toxicology of antisensetherapeutics. Toxicol Appl Pharmacol 2004; 201: 66-83.
44. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction ofapolipoprotein B and low-density lipoprotein cholesterol by shorttermadministration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35.
45. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, anapolipoprotein B synthesis inhibitor, for lowering of LDLcholesterol concentrations in patients with homozygous familialhypercholesterolaemia: a randomised, double-blind, placebocontrolledtrial. Lancet 2010; 375: 998-1006.
46. Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety ofmipomersen, an antisense inhibitor of apolipoprotein B, inhypercholesterolemic subjects receiving stable statin therapy. J AmColl Cardiol 2010; 55: 1611-8.
47. Bays HE, Davidson M, Jones MR, Abby SL. Effects ofcolesevelam hydrochloride on low-density lipoprotein cholesteroland high-sensitivity C-reactive protein when added to statins inpatients with hypercholesterolemia. Am J Cardiol 2006; 97: 1198-205.
48. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety ofezetimibe added to ongoing statin therapy for treatment of patientswith primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-91.
49. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the riskof coronary heart disease: 10,158 incident cases among 262,525participants in 29 Western prospective studies. Circulation 2007;115: 450-8.
50. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J.Triglycerides and small dense LDL: the twin Achilles heels of theFriedewald formula. Clin Biochem 2003; 36: 499-504.
51. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent andselective PPAR-alpha agonist in patients with atherogenicdyslipidemia or hypercholesterolemia: two randomized controlledtrials. JAMA 2007; 297: 1362-73.
52. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, anapolipoprotein B synthesis inhibitor, on low-density lipoproteincholesterol in patients with familial hypercholesterolemia. Am JCardiol 2010; 105: 1413-9.
53. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes inlipid levels from combined fluvastatin + fibrate (bezafibrate,fenofibrate, or gemfibrozil). Am J Cardiol 2003; 92: 794-7.
54. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusivecardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24: 2219-26.
55. Bennet A, Di AE, Erqou S, et al. Lipoprotein(a) levels and risk offuture coronary heart disease: large-scale prospective data. ArchIntern Med 2008; 168: 598-608.
56. Scanu AM, Bamba R. Niacin and lipoprotein(a): facts,uncertainties, and clinical considerations. Am J Cardiol 2008; 101:44B-7B.
57. Seed M, Knopp RH. Estrogens, lipoproteins, and cardiovascularrisk factors: an update following the randomized placebocontrolledtrials of hormone-replacement therapy. Curr OpinLipidol 2004; 15: 459-67.
58. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magneticresonance spectroscopy to measure hepatic triglyceride content:prevalence of hepatic steatosis in the general population. Am JPhysiol Endocrinol Metab 2005; 288: E462-E468.
59. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokineticinteraction of mipomersen sodium (ISIS 301012), a 2'-Omethoxyethylmodified antisense oligonucleotide targetingapolipoprotein B-100 messenger RNA, with simvastatin andezetimibe. Clin Pharmacokinet 2009; 48: 39-50.
60. Taylor S, Grimes P, Lim J, Im S, Lui H. Postinflammatoryhyperpigmentation. J Cutan Med Surg 2009; 13: 183-91.
61. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition ofmicrosomal triglyceride transfer protein in familialhypercholesterolemia. N Engl J Med 2007; 356: 148-56.
62. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transferprotein. Biochim Biophys Acta 1997; 1345: 136-50.
63. Yamaguchi K, Kitami N, Yamada T, Takazakura Y, Hashimoto H. [Lymphocyte stimulation test in halothane-induced hepatic injuryand its clinical observation]. Nippon Shokakibyo Gakkai Zasshi 1975; 72: 1023-31.
64. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowersLDL cholesterol in hyperlipidemic mice without causing hepaticsteatosis. J Lipid Res 2005; 46: 872-84.
65. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-Bsynthesis inhibition on liver triglyceride content in patients withfamilial hypercholesterolemia. J Lipid Res 2010; 51: 1057-62.
66. Yue P, Tanoli T, Wilhelm O, Patterson B, Yablonskiy D, Schonfeld G. Absence of fatty liver in familial hypobetalipoproteinemialinked to chromosome 3p21. Metabolism 2005; 54: 682-8.
67. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: fromsteatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
68. Ong JP, Pitts A, Younossi ZM. Increased overall mortality andliver-related mortality in non-alcoholic fatty liver disease. JHepatol 2008; 49: 608-12.
69. Ballestri S, Lonardo A, Losi L, Pellegrini E, Bertolotti M, Loria P. Do diabetes and obesity promote hepatic fibrosis in familialheterozygous hypobetalipoproteinemia? Intern Emerg Med 2009;4: 71-3.
70. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertasesubtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-densitylipoprotein receptor degradation and critical role in mouse liverregeneration. Hepatology 2008; 48: 646-54.
71. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH. Structuralrequirements for PCSK9-mediated degradation of the low-densitylipoprotein receptor. Proc Natl Acad Sci U S A 2008; 105: 13045-50.
72. McNutt MC, Lagace TA, Horton JD. Catalytic activity is notrequired for secreted PCSK9 to reduce low density lipoproteinreceptors in HepG2 cells. J Biol Chem 2007; 282: 20799-803.
73. Rudenko G, Henry L, Henderson K, et al. Structure of the LDLreceptor extracellular domain at endosomal pH. Science 2002; 298:2353-8.
74. Brown MS, Goldstein JL. Cholesterol feedback: fromSchoenheimer's bottle to Scap's MELADL. J Lipid Res 2009; 50 Suppl: S15-S27.
75. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase thatcoordinates LDL catabolism. J Lipid Res 2009; 50 Suppl: S172-S177.
76. Fisher TS, Lo SP, Pandit S, et al. Effects of pH and low densitylipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. JBiol Chem 2007; 282: 20502-12.
77. Stein EA. Other therapies for reducing low-density lipoproteincholesterol: medications in development. Endocrinol Metab ClinNorth Am 2009; 38: 99-119.
78. Alborn WE, Cao G, Careskey HE, et al. Serum proproteinconvertase subtilisin kexin type 9 is correlated directly with serumLDL cholesterol. Clin Chem 2007; 53: 1814-9.
79. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9preferentially reduces liver LDL receptors in mice. J Lipid Res 2008; 49: 1303-11.
80. Schmidt RJ, Beyer TP, Bensch WR, et al. Secreted proproteinconvertase subtilisin/kexin type 9 reduces both hepatic andextrahepatic low-density lipoprotein receptors in vivo. BiochemBiophys Res Commun 2008; 370: 634-40.
81. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: itsrole in LDL metabolism. Trends Biochem Sci 2007; 32: 71-7.
82. Kourimate S, Le MC, Langhi C, et al. Dual mechanisms for thefibrate-mediated repression of proprotein convertasesubtilisin/kexin type 9. J Biol Chem 2008; 283: 9666-73.
83. Langhi C, Le MC, Kourimate S, et al. Activation of the farnesoid Xreceptor represses PCSK9 expression in human hepatocytes. FEBSLett 2008; 582: 949-55.
84. Dubuc G, Tremblay M, Pare G, et al. A new method formeasurement of total plasma PCSK9: clinical applications. J LipidRes 2010; 51: 140-9.
85. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proproteinconvertase subtilisin/kexin type 9. J Lipid Res 2008; 49: 394-8.
86. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes offamilial hypercholesterolaemia in patients in the UK: relation toplasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43: 943-9.
87. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemiain four British families with the D374Y mutation in the PCSK9gene: long-term follow-up and treatment response. ArteriosclerThromb Vasc Biol 2005; 25: 2654-60.
88. Cameron J, Holla OL, Laerdahl JK, et al. Characterization of novelmutations in the catalytic domain of the PCSK9 gene. J Intern Med 2008; 263: 420-31.
89. Homer VM, Marais AD, Charlton F, et al. Identification andcharacterization of two non-secreted PCSK9 mutants associatedwith familial hypercholesterolemia in cohorts from New Zealandand South Africa. Atherosclerosis 2008; 196: 659-66.
90. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 causeautosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-6.
91. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequencevariations in PCSK9, low LDL, and protection against coronaryheart disease. N Engl J Med 2006; 354: 1264-72.
92. Kathiresan S. A PCSK9 missense variant associated with a reducedrisk of early-onset myocardial infarction. N Engl J Med 2008; 358:2299-300.
93. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-HansenA. PCSK9 R46L, low-density lipoprotein cholesterol levels, andrisk of ischemic heart disease: 3 independent studies and metaanalyses. J Am Coll Cardiol 2010; 55: 2833-42.
94. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679Xmutation in PCSK9 is present and lowers blood cholesterol in aSouthern African population. Atherosclerosis 2007; 193: 445-8.
95. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecularcharacterization of loss-of-function mutations in PCSK9 andidentification of a compound heterozygote. Am J Hum Genet 2006;79: 514-23.
96. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. ExpertOpin Ther Targets 2009; 13: 19-28.
97. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesteroland hypersensitivity to statins in mice lacking Pcsk9. Proc NatlAcad Sci U S A 2005; 102: 5374-9.
98. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisenseinhibition of proprotein convertase subtilisin/kexin type 9 reducesserum LDL in hyperlipidemic mice. J Lipid Res 2007; 48: 763-7.
99. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasmacholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105: 11915-20.
100. Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acidantisense oligonucleotide (LNA) silences PCSK9 and enhancesLDLR expression in vitro and in vivo. PLoS One 2010; 5: e10682.
101. Li H, Li H, Ziegler N, Cui R, Liu J. Recent patents on PCSK9: anew target for treating hypercholesterolemia. Recent Pat DNAGene Seq 2009; 3: 201-12.
102. Bell RM, Coleman RA. Enzymes of glycerolipid synthesis ineukaryotes. Annu Rev Biochem 1980; 49: 459-87.
103. Cases S, Smith SJ, Zheng YW, et al. Identification of a geneencoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A 1998; 95:13018-23.
104. Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related familymembers. J Biol Chem 2001; 276: 38870-6.
105. Cao J, Burn P, Shi Y. Properties of the mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2. J Biol Chem 2003; 278: 25657-63.
106. Turkish AR, Henneberry AL, Cromley D, et al. Identification oftwo novel human acyl-CoA wax alcohol acyltransferases: membersof the diacylglycerol acyltransferase 2 (DGAT2) gene superfamily. J Biol Chem 2005; 280: 14755-64.
107. Smith SJ, Cases S, Jensen DR, et al. Obesity resistance andmultiple mechanisms of triglyceride synthesis in mice lackingDgat. Nat Genet 2000; 25: 87-90.
108. Stone SJ, Myers HM, Watkins SM, et al. Lipopenia and skinbarrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004;279: 11767-76.
109. Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotidereduction of DGAT2 expression improves hepatic steatosis andhyperlipidemia in obese mice. Hepatology 2005; 42: 362-71.
110. Liu Y, Millar JS, Cromley DA, et al. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotidereduces VLDL TG and ApoB secretion in mice. Biochim Biophys Acta 2008; 1781: 97-104.
111. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator1beta (PGC-1beta), a novel PGC-1-related transcriptioncoactivator associated with host cell factor. J Biol Chem 2002; 277:1645-8.
112. Nagai Y, Yonemitsu S, Erion DM, et al. The role of peroxisomeproliferator-activated receptor gamma coactivator-1 beta in thepathogenesis of fructose-induced insulin resistance. Cell Metab 2009; 9: 252-64.
113. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperateswith peroxisome proliferator-activated receptor alpha in transcriptionalcontrol of nuclear genes encoding mitochondrial fattyacid oxidation enzymes. Mol Cell Biol 2000; 20: 1868-76.
114. Lin J, Yang R, Tarr PT, et al. Hyperlipidemic effects of dietarysaturated fats mediated through PGC-1beta coactivation of SREBP. Cell 2005; 120: 261-73.
115. Jiang HP, Serrero G. Isolation and characterization of a full-lengthcDNA coding for an adipose differentiation-related protein. ProcNatl Acad Sci U S A 1992; 89: 7856-60.
116. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is anubiquitously expressed lipid storage droplet-associated protein. JLipid Res 1997; 38: 2249-63.
117. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diversecell types and diseases. Cell Tissue Res 1998; 294: 309-21.
118. Gao J, Serrero G. Adipose differentiation related protein (ADRP)expressed in transfected COS-7 cells selectively stimulates longchain fatty acid uptake. J Biol Chem 1999; 274: 16825-30.
119. Imamura M, Inoguchi T, Ikuyama S, et al. ADRP stimulates lipidaccumulation and lipid droplet formation in murine fibroblasts. AmJ Physiol Endocrinol Metab 2002; 283: E775-E783.
120. Larigauderie G, Furman C, Jaye M, et al. Adipophilin enhanceslipid accumulation and prevents lipid efflux from THP-1macrophages: potential role in atherogenesis. Arterioscler ThrombVasc Biol 2004; 24: 504-10.
121. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation insteatotic hepatocytes. Am J Physiol Endocrinol Metab 2005; 288:E1195-E1205.
122. Motomura W, Inoue M, Ohtake T, et al. Up-regulation of ADRP infatty liver in human and liver steatosis in mice fed with high fatdiet. Biochem Biophys Res Commun 2006; 340: 1111-8.
123. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS. Reduction of hepatosteatosis and lipid levels by an adiposedifferentiation-related protein antisense oligonucleotide. Gastroenterology 2007; 132: 1947-54.
124. Brown JM, Rudel LL. Stearoyl-coenzyme A desaturase 1 inhibitionand the metabolic syndrome: considerations for future drugdiscovery. Curr Opin Lipidol 2010; 21: 192-7.
125. Mauvoisin D, Mounier C. Hormonal and nutritional regulation ofSCD1 gene expression. Biochimie 2011; 93: 78-86.
126. Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desaturasesand role in metabolism. Prog Lipid Res 2004; 43: 91-104.
127. Brown JM, Chung S, Sawyer JK, et al. Inhibition of stearoylcoenzymeA desaturase 1 dissociates insulin resistance and obesityfrom atherosclerosis. Circulation 2008; 118: 1467-75.
128. Brown JM, Chung S, Sawyer JK, et al. Combined therapy ofdietary fish oil and stearoyl-CoA desaturase 1 inhibition preventsthe metabolic syndrome and atherosclerosis. Arterioscler ThrombVasc Biol 2010; 30: 24-30.
129. Savransky V, Jun J, Li J, et al. Dyslipidemia and atherosclerosisinduced by chronic intermittent hypoxia are attenuated bydeficiency of stearoyl coenzyme A desaturase. Circ Res 2008; 103:1173-80.